Core Viewpoint - Angelalign Technology Co., Ltd. is facing a temporary injunction from the Unified Patent Court of Düsseldorf, requiring the company to suspend certain modules of its "live now" automatic update feature, which minimally impacts doctors and patients using its invisible orthodontic products [1] Group 1: Legal Developments - The temporary injunction applies only to certain European countries, excluding Spain, Switzerland, the UK, and Ireland [1] - The company plans to launch a new upgraded iPlan feature for affected European users, which will offer equal reliability and greater flexibility [1] - Angelalign asserts that the Live Now feature in its iOrtho treatment design software does not infringe on any valid patents held by Align Technology [1] Group 2: Company Position and Strategy - Angelalign has filed a patent opposition application with the European Patent Office, arguing that the patent in question lacks novelty and inventiveness compared to existing technology, seeking a permanent invalidation of the patent [1] - The company respects the court's ruling but intends to actively provide evidence to demonstrate the unreasonableness of the injunction [2] - Angelalign has a strong focus on innovation in the invisible orthodontics field, with several award-winning solutions and products, and aims to foster a fair and healthy competitive environment for the benefit of doctors and patients [2] Group 3: Market Performance and Growth - Angelalign has received high satisfaction ratings from doctors and has successfully transformed complex clinical concepts into practical solutions through its flexible manufacturing system [2] - The company has achieved strong global growth and aims to maintain this growth trend through continuous innovation [2]